Investment3 Sept 2025, 12:12 pm
Welcure Drugs & Pharmaceuticals to Receive Strategic Equity Investment from Telexcell Trade PTE LTD, Singapore
AI Summary
Welcure Drugs & Pharmaceuticals Ltd. has executed a Letter of Intent (LOI) with Telexcell Trade PTE LTD, Singapore, outlining their intent to acquire a strategic equity stake in the Company. The investor, Telexcell Trade PTE LTD, plans to acquire up to 25% equity in Welcure Drugs & Pharmaceuticals Ltd at an indicative price of 320 per share, representing a premium to the current market price. The transaction is an all-cash deal, subject to necessary due diligence, approvals, and compliance with applicable laws. The strategic rationale behind this investment is to strengthen Welcure’s global footprint in the pharmaceutical and chemical exports sector, particularly in light of growing opportunities across emerging markets.
Key Highlights
- Telexcell Trade PTE LTD, Singapore to acquire up to 25% equity in Welcure Drugs & Pharmaceuticals Ltd.
- Indicative price of 320 per share, representing a premium to the current market price.
- All-cash transaction subject to necessary due diligence, approvals, and compliance with applicable laws.
- Investment aims to strengthen Welcure’s global footprint in the pharmaceutical and chemical exports sector.
- Subject to completion of satisfactory due diligence, execution of definitive agreements, and receipt of requisite approvals.